Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 10/20 | 1.00 |
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | TDO2 | P48775 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2396372 | 1.00 | SCN4A (1.00) | SCN4ATACR1PPARGPPARAIDO1 | |
| SCHEMBL4345367 | 0.87 | SCN4A (1.00) | SCN4ATACR1 | |
| SCHEMBL12847267 | 0.87 | SCN4A (1.00) | SCN4ATACR1 | |
| SCHEMBL12266575 | 0.82 | SCN4A (0.76) | SCN4ATACR1CA12CA1CA2 | |
| SCHEMBL15326789 | 0.82 | SCN4A (0.76) | SCN4ATACR1CYP1A2 | |
| SCHEMBL1496649 | 0.79 | SCN4A (0.65) | SCN4APPARGPPARACYP1A2 | |
| SCHEMBL19686196 | 0.79 | SCN4A (0.76) | SCN4A | |
| SCHEMBL19685926 | 0.77 | SCN4A (0.68) | SCN4ATACR1 | |
| SCHEMBL2397106 | 0.76 | SCN4A (0.61) | SCN4ATACR1IDO1TDO2CYP1A2 | |
| SCHEMBL3441819 | 0.76 | SCN4A (0.61) | SCN4APPARGPPARACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212199-B2 | Catalyst compounds | THE UNIVERSITY OF LIVERPOOL (GB) | 2015-12-15 | — | — | US | disclosed |
| US-9212199-B2 | Catalyst compounds | THE UNIVERSITY OF LIVERPOOL (GB) | 2015-12-15 | — | — | US | disclosed |
| US-20150080592-A1 | CATALYST COMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2015-03-19 | — | — | US | disclosed |
| US-20150080592-A1 | CATALYST COMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2015-03-19 | — | — | US | disclosed |
| WO-2013153407-A1 | CATALYST COMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2013-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080592-A1 | CATALYST COMPOUNDS | IDH3B, IDH2, NQO1 | SCN4A 3558/4885TACR1 3073/4885PPARG 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.